{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T21:14:02Z","timestamp":1783545242501,"version":"3.55.0"},"reference-count":121,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,7]]},"DOI":"10.1097\/nrl.0b013e31816f27fe","type":"journal-article","created":{"date-parts":[[2008,7,3]],"date-time":"2008-07-03T07:06:18Z","timestamp":1215068778000},"page":"207-223","source":"Crossref","is-referenced-by-count":29,"title":["Acute Inflammatory Demyelinating Optic Neuritis"],"prefix":"10.1097","volume":"14","author":[{"given":"Nuhad Abou","family":"Zeid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M Tariq","family":"Bhatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-1-20210211","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1001\/archopht.1972.01000020137004","article-title":"Optic neuritis and multiple sclerosis. An epidemiologic study.","volume":"87","author":"Percy","year":"1972","journal-title":"Arch Ophthalmol"},{"key":"R2-1-20210211","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1212\/WNL.45.2.244","article-title":"Optic neuritis: a population-based study in Olmsted County, Minnesota.","volume":"45","author":"Rodriguez","year":"1995","journal-title":"Neurology"},{"issue":"20","key":"R3-1-20210211","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJM200011163432001","article-title":"Relapses and progression of disability in multiple sclerosis.","volume":"343","author":"Confavreux","year":"2000","journal-title":"NEJM"},{"key":"R4-1-20210211","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1136\/bmj.4.5893.661","article-title":"Visual evoked response in diagnosis of multiple sclerosis.","volume":"4","author":"Halliday","year":"1973","journal-title":"Br Med J"},{"key":"R5-1-20210211","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1001\/archneur.1985.04060070098026","article-title":"Optic neuritis or multiple sclerosis.","volume":"42","author":"Kurtzke","year":"1985","journal-title":"Arch Neurol"},{"key":"R6-1-20210211","first-page":"727","article-title":"Multiple sclerosis risk after optic neuritis: final follow-up from the Optic Neuritis Treatment Trial.","volume":"65","year":"2008","journal-title":"Arch Neurol"},{"key":"R7-1-20210211","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/brain\/awm329","article-title":"Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis.","author":"Fisniku","year":"2008","journal-title":"Brain"},{"key":"R8-1-20210211","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S1091-8531(99)70078-9","article-title":"Optic neuritis in children: clinical features and visual outcome.","volume":"3","author":"Brady","year":"1999","journal-title":"J AAPOS"},{"key":"R9-1-20210211","first-page":"254","article-title":"Optic neuritis in children.","volume":"37","author":"Morales","year":"2000","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"R10-1-20210211","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1212\/WNL.49.5.1413","article-title":"Risk factors for developing multiple sclerosis after childhood optic neuritis.","volume":"49","author":"Lucchinetti","year":"1997","journal-title":"Neurology"},{"key":"R11-1-20210211","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1212\/01.wnl.0000224757.69746.fb","article-title":"The clinical features, MRI findings, and outcome of optic neuritis in children.","volume":"67","author":"Wilejto","year":"2006","journal-title":"Neurology"},{"key":"R12-1-20210211","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1080\/08820530390895172","article-title":"Optic neuritis in adults and children.","volume":"18","author":"Boomer","year":"2003","journal-title":"Semin Ophthalmol"},{"key":"R13-1-20210211","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0161-6420(90)32583-6","article-title":"Bilateral postinfectious optic neuritis and intravenous steroid therapy in children.","volume":"97","author":"Farris","year":"1990","journal-title":"Ophthalmology"},{"key":"R14-1-20210211","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0022-510X(02)00043-6","article-title":"Devic's neuromyelitis optica: clinical, laboratory, MRI and outcome profile.","volume":"197","author":"de Seze","year":"2002","journal-title":"J Neurol Sci"},{"key":"R15-1-20210211","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1191\/1352458503ms947oa","article-title":"Is Devic's neuromyelitis optica a separate disease? A comparative study with multiple sclerosis.","volume":"9","author":"de Seze","year":"2003","journal-title":"Mult Scler"},{"key":"R16-1-20210211","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","article-title":"The clinical course of neuromyelitis optica (Devic's syndrome).","volume":"53","author":"Wingerchuk","year":"1999","journal-title":"Neurology"},{"key":"R17-1-20210211","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1212\/01.WNL.0000049912.02954.2C","article-title":"Neuromyelitis optica: clinical predictors of a relapsing course and survival.","volume":"60","author":"Wingerchuk","year":"2003","journal-title":"Neurology"},{"key":"R18-1-20210211","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1001\/archneur.63.3.390","article-title":"Brain abnormalities in neuromyelitis optica.","volume":"63","author":"Pittock","year":"2006","journal-title":"Arch Neurol"},{"key":"R19-1-20210211","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1136\/jnnp.60.4.382","article-title":"Clinical, CSF, and MRI findings in Devic's neuromyelitis optica.","volume":"60","author":"O'Riordan","year":"1996","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R20-1-20210211","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel.","volume":"202","author":"Lennon","year":"2005","journal-title":"J Exp Med"},{"key":"R21-1-20210211","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis.","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"key":"R22-1-20210211","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1155\/2006\/586306","article-title":"NMO-IgG: a specific biomarker for neuromyelitis optica.","volume":"22","author":"Weinshenker","year":"2006","journal-title":"Dis Markers"},{"key":"R23-1-20210211","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/01.nrl.0000250927.21903.f8","article-title":"Diagnosis and treatment of neuromyelitis optica.","volume":"13","author":"Wingerchuk","year":"2007","journal-title":"Neurologist"},{"key":"R24-1-20210211","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","article-title":"Revised diagnostic criteria for neuromyelitis optica.","volume":"66","author":"Wingerchuk","year":"2006","journal-title":"Neurology"},{"key":"R25-1-20210211","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s11940-005-0010-6","article-title":"Neuromyelitis optica.","volume":"7","author":"Wingerchuk","year":"2005","journal-title":"Curr Treat Options Neurol"},{"key":"R26-1-20210211","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1212\/WNL.58.1.143","article-title":"Plasma exchange for severe attacks of CNS demyelination: predictors of response.","volume":"58","author":"Keegan","year":"2002","journal-title":"Neurology"},{"key":"R27-1-20210211","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/1531-8249(199912)46:6<878::AID-ANA10>3.0.CO;2-Q","article-title":"A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease.","volume":"46","author":"Weinshenker","year":"1999","journal-title":"Ann Neurol"},{"key":"R28-1-20210211","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1001\/archopht.1991.01080120057025","article-title":"The clinical profile of optic neuritis. Experience of the Optic Neuritis Treatment Trial. Optic Neuritis Study Group.","volume":"109","year":"1991","journal-title":"Arch Ophthalmol"},{"key":"R29-1-20210211","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1001\/archopht.1993.01090020085029","article-title":"Baseline visual field profile of optic neuritis. The experience of the optic neuritis treatment trial. Optic Neuritis Study Group.","volume":"111","author":"Keltner","year":"1993","journal-title":"Arch Ophthalmol"},{"key":"R30-1-20210211","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/00041327-199512000-00047","article-title":"Uhthoff and his symptom.","volume":"15","author":"Selhorst","year":"1995","journal-title":"J Neuroophthalmol"},{"key":"R31-1-20210211","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/ana.410300209","article-title":"Uhthoff's symptom in optic neuritis: relationship to magnetic resonance imaging and development of multiple sclerosis.","volume":"30","author":"Scholl","year":"1991","journal-title":"Ann Neurol"},{"key":"R32-1-20210211","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/j.1755-3768.1978.tb06646.x","article-title":"Pulfrich pendulum phenomenon in patients with a history of acute optic neuritis.","volume":"56","author":"Slagsvold","year":"1978","journal-title":"Acta Ophthalmol (Copenh)"},{"key":"R33-1-20210211","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0002-9394(03)00862-6","article-title":"Visual function more than 10 years after optic neuritis: experience of the optic neuritis treatment trial.","volume":"137","author":"Beck","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"R34-1-20210211","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/S0161-6420(95)30839-1","article-title":"What we have learned from the Optic Neuritis Treatment Trial.","volume":"102","author":"Beck","year":"1995","journal-title":"Ophthalmology"},{"key":"R35-1-20210211","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1001\/archopht.1997.01100160578009","article-title":"Does optic disc appearance distinguish ischemic optic neuropathy from optic neuritis?","volume":"115","author":"Warner","year":"1997","journal-title":"Arch Ophthalmol"},{"key":"R36-1-20210211","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1016\/S0161-6420(94)31103-1","article-title":"The course of visual recovery after optic neuritis. Experience of the Optic Neuritis Treatment Trial.","volume":"101","author":"Beck","year":"1994","journal-title":"Ophthalmology"},{"key":"R37-1-20210211","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1212\/WNL.49.5.1404","article-title":"The 5-year risk of MS after optic neuritis. Experience of the optic neuritis treatment trial. Optic Neuritis Study Group.","volume":"49","year":"1997","journal-title":"Neurology"},{"key":"R38-1-20210211","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1001\/archopht.121.7.944","article-title":"High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the optic neuritis treatment trial.","volume":"121","author":"Beck","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"R39-1-20210211","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1212\/WNL.46.2.368","article-title":"Cerebrospinal fluid in acute optic neuritis: experience of the optic neuritis treatment trial.","volume":"46","author":"Rolak","year":"1996","journal-title":"Neurology"},{"key":"R40-1-20210211","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1212\/WNL.38.2.180","article-title":"MRI in the diagnosis of MS: a prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT.","volume":"38","author":"Paty","year":"1988","journal-title":"Neurology"},{"key":"R41-1-20210211","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1001\/archneur.1993.00540080050013","article-title":"Brain magnetic resonance imaging in acute optic neuritis. Experience of the Optic Neuritis Study Group.","volume":"50","author":"Beck","year":"1993","journal-title":"Arch Neurol"},{"key":"R42-1-20210211","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/S0161-6420(92)31892-5","article-title":"Enhancement and demyelination of the intraorbital optic nerve. Fat suppression magnetic resonance imaging.","volume":"99","author":"Guy","year":"1992","journal-title":"Ophthalmology"},{"key":"R43-1-20210211","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/S0161-6420(02)01148-X","article-title":"Use of magnetic resonance imaging to differentiate optic neuritis and nonarteritic anterior ischemic optic neuropathy.","volume":"109","author":"Rizzo","year":"2002","journal-title":"Ophthalmology"},{"key":"R44-1-20210211","first-page":"1310","article-title":"Optic neuropathy secondary to cat scratch disease: distinguishing MR imaging features from other types of optic neuropathies.","volume":"26","author":"Schmalfuss","year":"2005","journal-title":"AJNR Am J Neuroradiol"},{"key":"R45-1-20210211","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/S0161-6420(99)90482-7","article-title":"The impact of the optic neuritis treatment trial on the practices of ophthalmologists and neurologists.","volume":"106","author":"Trobe","year":"1999","journal-title":"Ophthalmology"},{"key":"R46-1-20210211","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1159\/000069408","article-title":"Perils and pitfalls in the interpretation of clinical trials: a reflection on the recent experience in multiple sclerosis.","volume":"18","author":"Goodin","year":"1999","journal-title":"Neuroepidemiology"},{"key":"R47-1-20210211","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199202273260901","article-title":"A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group.","volume":"326","author":"Beck","year":"1992","journal-title":"N Engl J Med"},{"key":"R48-1-20210211","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1056\/NEJM199312093292403","article-title":"The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group.","volume":"329","author":"Beck","year":"1993","journal-title":"N Engl J Med"},{"key":"R49-1-20210211","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0197-2456(93)90015-6","article-title":"Design, methods, and conduct of the Optic Neuritis Treatment Trial.","volume":"14","author":"Cleary","year":"1993","journal-title":"Control Clin Trials"},{"key":"R50-1-20210211","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0021-5155(98)00071-9","article-title":"Multicenter clinical trial for evaluating methylprednisolone pulse treatment of idiopathic optic neuritis in Japan. Optic Neuritis Treatment Trial Multicenter Cooperative Research Group (ONMRG).","volume":"43","author":"Wakakura","year":"1999","journal-title":"Jpn J Ophthalmol"},{"key":"R51-1-20210211","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0021-5155(98)00072-0","article-title":"Baseline features of idiopathic optic neuritis as determined by a multicenter treatment trial in Japan. Optic Neuritis Treatment Trial Multicenter Cooperative Research Group (ONMRG).","volume":"43","author":"Wakakura","year":"1999","journal-title":"Jpn J Ophthalmol"},{"key":"R52-1-20210211","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1212\/WNL.52.7.1479","article-title":"A randomized, controlled trial of oral high-dose methylprednisolone in acute optic neuritis.","volume":"52","author":"Sellebjerg","year":"1999","journal-title":"Neurology"},{"key":"R53-1-20210211","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1212\/WNL.54.11.2039","article-title":"Practice parameter: the role of corticosteroids in the management of acute monosymptomatic optic neuritis. Report of the Quality Standards Subcommittee of the American Academy of Neurology.","volume":"54","author":"Kaufman","year":"2000","journal-title":"Neurology"},{"key":"R54-1-20210211","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s004150070172","article-title":"Steroids for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials.","volume":"247","author":"Brusaferri","year":"2000","journal-title":"J Neurol"},{"key":"R55-1-20210211","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1212\/WNL.50.1.230","article-title":"Effects of intravenous methylprednisolone on outcome in MRI-based prognostic subgroups in acute optic neuritis.","volume":"50","author":"Kapoor","year":"1998","journal-title":"Neurology"},{"issue":"1","key":"R56-1-20210211","first-page":"CD001430","article-title":"Corticosteroids for treating optic neuritis.","author":"Vedula","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"R57-1-20210211","first-page":"CD001331","article-title":"Corticosteroids or ACTH for acute exacerbations in multiple sclerosis.","author":"Filippini","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"R58-1-20210211","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/135245850000600408","article-title":"A meta-analysis of methylprednisolone in recovery from multiple sclerosis exacerbations.","volume":"6","author":"Miller","year":"2000","journal-title":"Mult Scler"},{"key":"R59-1-20210211","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1212\/01.WNL.0000138572.82125.F5","article-title":"The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis.","volume":"63","author":"Morrow","year":"2004","journal-title":"Neurology"},{"key":"R60-1-20210211","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1159\/000117038","article-title":"Double-blind trial of dexamethasone versus methylprednisolone in multiple sclerosis acute relapses.","volume":"34","author":"La Mantia","year":"1994","journal-title":"Eur Neurol"},{"key":"R61-1-20210211","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1212\/WNL.56.11.1514","article-title":"A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis.","volume":"56","author":"Noseworthy","year":"2001","journal-title":"Neurology"},{"issue":"suppl","key":"R62-1-20210211","first-page":"A32","article-title":"IVIg treatment of optic neuritis following second eye involvement.","volume":"52","author":"Bhatti","year":"1999","journal-title":"Neurology"},{"key":"R63-1-20210211","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1212\/01.WNL.0000152873.82631.B3","article-title":"A double-blind, randomized trial of IV immunoglobulin treatment in acute optic neuritis.","volume":"64","author":"Roed","year":"2005","journal-title":"Neurology"},{"key":"R64-1-20210211","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1212\/01.WNL.0000138437.99046.6B","article-title":"Plasma exchange for severe optic neuritis: treatment of 10 patients.","volume":"63","author":"Ruprecht","year":"2004","journal-title":"Neurology"},{"key":"R65-1-20210211","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S1474-4422(05)70071-5","article-title":"Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis.","volume":"4","author":"Miller","year":"2005","journal-title":"Lancet Neurol"},{"key":"R66-1-20210211","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/ana.410130302","article-title":"New diagnostic criteria for multiple sclerosis: guidelines for research protocols.","volume":"13","author":"Poser","year":"1983","journal-title":"Ann Neurol"},{"key":"R67-1-20210211","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/ana.1032","article-title":"Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.","volume":"50","author":"McDonald","year":"2001","journal-title":"Ann Neurol"},{"key":"R68-1-20210211","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/ana.10240","article-title":"Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis.","volume":"52","author":"Dalton","year":"2002","journal-title":"Ann Neurol"},{"key":"R69-1-20210211","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S1474-4422(06)70353-2","article-title":"MRI criteria for dissemination in space in patients with clinically isolated syndromes: a multicentre follow-up study.","volume":"5","author":"Korteweg","year":"2006","journal-title":"Lancet Neurol"},{"key":"R70-1-20210211","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1212\/WNL.60.1.27","article-title":"New diagnostic criteria for multiple sclerosis: application in first demyelinating episode.","volume":"60","author":"Tintore","year":"2003","journal-title":"Neurology"},{"key":"R71-1-20210211","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/brain\/121.3.495","article-title":"The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up.","volume":"121","author":"O'Riordan","year":"1998","journal-title":"Brain"},{"key":"R72-1-20210211","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1136\/jnnp.50.6.758","article-title":"A reassessment of the risk of multiple sclerosis developing in patients with optic neuritis after extended follow-up.","volume":"50","author":"Francis","year":"1987","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R73-1-20210211","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1212\/WNL.38.2.185","article-title":"Risk of developing multiple sclerosis after uncomplicated optic neuritis: a long-term prospective study.","volume":"38","author":"Rizzo","year":"1988","journal-title":"Neurology"},{"key":"R74-1-20210211","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/ana.410270406","article-title":"A long-term prospective study of optic neuritis: evaluation of risk factors.","volume":"27","author":"Sandberg-Wollheim","year":"1990","journal-title":"Ann Neurol"},{"key":"R75-1-20210211","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMoa011341","article-title":"A longitudinal study of abnormalities on MRI and disability from multiple sclerosis.","volume":"346","author":"Brex","year":"2002","journal-title":"N Engl J Med"},{"key":"R76-1-20210211","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1212\/01.WNL.0000082654.99838.EF","article-title":"The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.","volume":"61","author":"Frohman","year":"2003","journal-title":"Neurology"},{"key":"R77-1-20210211","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1001\/archneur.61.9.1386","article-title":"Neurologic impairment 10 years after optic neuritis.","volume":"61","author":"Beck","year":"2004","journal-title":"Arch Neurol"},{"key":"R78-1-20210211","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1212\/01.wnl.0000237354.10144.ec","article-title":"Baseline MRI predicts future attacks and disability in clinically isolated syndromes.","volume":"67","author":"Tintore","year":"2006","journal-title":"Neurology"},{"issue":"suppl","key":"R79-1-20210211","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1002\/ana.410360704","article-title":"Natural history of multiple sclerosis.","volume":"36","author":"Weinshenker","year":"1994","journal-title":"Ann Neurol"},{"key":"R80-1-20210211","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/brain\/116.1.117","article-title":"Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up.","volume":"116","author":"Runmarker","year":"1993","journal-title":"Brain"},{"key":"R81-1-20210211","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/ana.20363","article-title":"Is optic neuritis more benign than other first attacks in multiple sclerosis?","volume":"57","author":"Tintore","year":"2005","journal-title":"Ann Neurol"},{"key":"R82-1-20210211","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1056\/NEJMoa022328","article-title":"Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event.","volume":"349","author":"Berger","year":"2003","journal-title":"N Engl J Med"},{"key":"R83-1-20210211","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1056\/NEJMoa063602","article-title":"Lack of association between antimyelin antibodies and progression to multiple sclerosis.","volume":"356","author":"Kuhle","year":"2007","journal-title":"N Engl J Med"},{"key":"R84-1-20210211","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1191\/135248506ms1263oa","article-title":"Axonal damage markers in the cerebrospinal fluid of patients with clinically isolated syndrome improve predicting conversion to definite multiple sclerosis.","volume":"12","author":"Brettschneider","year":"2006","journal-title":"Mult Scler"},{"key":"R85-1-20210211","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1212\/01.wnl.0000252357.30287.1d","article-title":"Soluble Nogo-A, an inhibitor of axonal regeneration, as a biomarker for multiple sclerosis.","volume":"68","author":"Jurewicz","year":"2007","journal-title":"Neurology"},{"key":"R86-1-20210211","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1056\/NEJM199801293380502","article-title":"Axonal transection in the lesions of multiple sclerosis.","volume":"338","author":"Trapp","year":"1998","journal-title":"N Engl J Med"},{"key":"R87-1-20210211","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0022-510X(02)00069-2","article-title":"Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease.","volume":"206","author":"Bjartmar","year":"2003","journal-title":"J Neurol Sci"},{"key":"R88-1-20210211","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1212\/WNL.59.1.126","article-title":"Normal-appearing brain tissue MTR histograms in clinically isolated syndromes suggestive of MS..","volume":"59","author":"Traboulsee","year":"2002","journal-title":"Neurology"},{"key":"R89-1-20210211","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1093\/brain\/awf240","article-title":"Brain metabolite changes in cortical grey and normal-appearing white matter in clinically early relapsing-remitting multiple sclerosis.","volume":"125","author":"Chard","year":"2002","journal-title":"Brain"},{"key":"R90-1-20210211","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jns.2005.08.019","article-title":"Multiple sclerosis-related cognitive changes: a review of cross-sectional and longitudinal studies.","volume":"245","author":"Amato","year":"2006","journal-title":"J Neurol Sci"},{"key":"R91-1-20210211","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1093\/brain\/awf025","article-title":"Brain atrophy in clinically early relapsing-remitting multiple sclerosis.","volume":"125","author":"Chard","year":"2002","journal-title":"Brain"},{"key":"R92-1-20210211","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1007\/s00415-006-0503-6","article-title":"Cortical atrophy is relevant in multiple sclerosis at clinical onset.","volume":"254","author":"Calabrese","year":"2007","journal-title":"J Neurol"},{"key":"R93-1-20210211","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1136\/jnnp.70.6.773","article-title":"A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis.","volume":"70","author":"Zivadinov","year":"2001","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R94-1-20210211","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1093\/brain\/awh126","article-title":"Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes.","volume":"127","author":"Dalton","year":"2004","journal-title":"Brain"},{"key":"R95-1-20210211","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1177\/1352458506071196","article-title":"Early cognitive impairment in patients with clinically isolated syndrome suggestive of multiple sclerosis.","volume":"13","author":"Feuillet","year":"2007","journal-title":"Mult Scler"},{"key":"R96-1-20210211","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1056\/NEJM200009283431301","article-title":"Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group.","volume":"343","author":"Jacobs","year":"2000","journal-title":"N Engl J Med"},{"key":"R97-1-20210211","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/S0140-6736(00)04725-5","article-title":"Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study.","volume":"357","author":"Comi","year":"2001","journal-title":"Lancet"},{"key":"R98-1-20210211","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1212\/01.wnl.0000237641.33768.8d","article-title":"Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes.","volume":"67","author":"Kappos","year":"2006","journal-title":"Neurology"},{"key":"R99-1-20210211","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/ana.10148","article-title":"Interferon beta-1a for early multiple sclerosis: CHAMPS trial subgroup analyses.","volume":"51","author":"Beck","year":"2002","journal-title":"Ann Neurol"},{"key":"R100-1-20210211","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1016\/S0149-2918(03)80339-9","article-title":"The effects of intramuscular interferon beta-Ia in patients at high risk for development of multiple sclerosis: a post hoc analysis of data from CHAMPS.","volume":"25","author":"O'Connor","year":"2003","journal-title":"Clin Ther"},{"key":"R101-1-20210211","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1212\/01.wnl.0000200778.65597.ae","article-title":"IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event.","volume":"66","author":"Kinkel","year":"2006","journal-title":"Neurology"},{"key":"R102-1-20210211","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0140-6736(07)61194-5","article-title":"Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study.","volume":"370","author":"Kappos","year":"2007","journal-title":"Lancet"},{"key":"R103-1-20210211","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1046\/j.1468-1331.2002.00501.x","article-title":"Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysis.","volume":"9","author":"Sorensen","year":"2002","journal-title":"Eur J Neurol"},{"key":"R104-1-20210211","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1212\/WNL.43.5.905","article-title":"Assessment of MRI criteria for a diagnosis of MS.","volume":"43","author":"Offenbacher","year":"1993","journal-title":"Neurology"},{"key":"R105-1-20210211","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1001\/archneur.61.10.1515","article-title":"Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled trial.","volume":"61","author":"Achiron","year":"2004","journal-title":"Arch Neurol"},{"key":"R106-1-20210211","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1471-2377-6-19","article-title":"Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis\u2014reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations.","volume":"6","author":"Then Bergh","year":"2006","journal-title":"BMC Neurol"},{"key":"R107-1-20210211","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1212\/WNL.57.7.1239","article-title":"Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS.","volume":"57","author":"Zivadinov","year":"2001","journal-title":"Neurology"},{"key":"R108-1-20210211","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1001\/archneur.63.4.611","article-title":"Not every patient with multiple sclerosis should be treated at time of diagnosis.","volume":"63","author":"Pittock","year":"2006","journal-title":"Arch Neurol"},{"key":"R109-1-20210211","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1001\/archneur.63.4.614","article-title":"Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis.","volume":"63","author":"Frohman","year":"2006","journal-title":"Arch Neurol"},{"key":"R110-1-20210211","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/ana.20197","article-title":"Clinical implications of benign multiple sclerosis: a 20-year population-based follow-up study.","volume":"56","author":"Pittock","year":"2004","journal-title":"Ann Neurol"},{"key":"R111-1-20210211","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1007\/s00415-006-0161-8","article-title":"Benign multiple sclerosis: cognitive, psychological and social aspects in a clinical cohort.","volume":"253","author":"Amato","year":"2006","journal-title":"J Neurol"},{"key":"R112-1-20210211","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1212\/01.wnl.0000253185.03943.66","article-title":"Longitudinal follow-up of \u201cbenign\u201d multiple sclerosis at 20 years.","volume":"68","author":"Sayao","year":"2007","journal-title":"Neurology"},{"key":"R113-1-20210211","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1126\/science.1957169","article-title":"Optical coherence tomography.","volume":"254","author":"Huang","year":"1991","journal-title":"Science"},{"key":"R114-1-20210211","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/00055735-199906000-00006","article-title":"Clinical applications of optical coherence tomography.","volume":"10","author":"Baumal","year":"1999","journal-title":"Curr Opin Ophthalmol"},{"key":"R115-1-20210211","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S1474-4422(06)70573-7","article-title":"Optical coherence tomography in multiple sclerosis.","volume":"5","author":"Frohman","year":"2006","journal-title":"Lancet Neurol"},{"key":"R116-1-20210211","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jns.2006.08.012","article-title":"Imaging of the optic disc and retinal nerve fiber layer in acute optic neuritis.","volume":"250","author":"Pro","year":"2006","journal-title":"J Neurol Sci"},{"key":"R117-1-20210211","first-page":"2520","article-title":"Correlation between morphological and functional retinal impairment in multiple sclerosis patients.","volume":"40","author":"Parisi","year":"1999","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R118-1-20210211","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/ana.20575","article-title":"Retinal nerve fiber layer axonal loss and visual dysfunction in optic neuritis.","volume":"58","author":"Trip","year":"2005","journal-title":"Ann Neurol"},{"key":"R119-1-20210211","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/ana.20851","article-title":"Quantifying axonal loss after optic neuritis with optical coherence tomography.","volume":"59","author":"Costello","year":"2006","journal-title":"Ann Neurol"},{"key":"R120-1-20210211","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ophtha.2005.10.040","article-title":"Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis.","volume":"113","author":"Fisher","year":"2006","journal-title":"Ophthalmology"},{"key":"R121-1-20210211","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1212\/01.wnl.0000260612.51849.ed","article-title":"Diagnostic accuracy of retinal abnormalities in predicting disease activity in MS.","volume":"68","author":"Sepulcre","year":"2007","journal-title":"Neurology"}],"container-title":["The Neurologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/NRL.0b013e31816f27fe","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T04:40:45Z","timestamp":1620967245000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00127893-200807000-00001"}},"subtitle":["Evidence-Based Visual and Neurological Considerations"],"short-title":[],"issued":{"date-parts":[[2008,7]]},"references-count":121,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/nrl.0b013e31816f27fe","relation":{},"ISSN":["1074-7931"],"issn-type":[{"value":"1074-7931","type":"print"}],"subject":[],"published":{"date-parts":[[2008,7]]}}}